These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8649855)

  • 1. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
    Deppert W; Göhler T; Koga H; Kim E
    J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
    Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
    Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
    Srinivasan R; Maxwell SA
    Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into p53 function from structural studies.
    Arrowsmith CH; Morin P
    Oncogene; 1996 Apr; 12(7):1379-85. PubMed ID: 8622853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-specific interaction of a conformational domain of p53 with DNA.
    Srinivasan R; Roth JA; Maxwell SA
    Cancer Res; 1993 Nov; 53(22):5361-4. PubMed ID: 8221671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
    Stros M; Muselíková-Polanská E; Pospísilová S; Strauss F
    Biochemistry; 2004 Jun; 43(22):7215-25. PubMed ID: 15170359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
    Niewolik D; Vojtesek B; Kovarik J
    Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.
    Kim E; Albrechtsen N; Deppert W
    Oncogene; 1997 Aug; 15(7):857-69. PubMed ID: 9266973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies.
    Cook JL; Ré RN; Giardina JF; Fontenot FE; Cheng DY; Alam J
    Oncogene; 1995 Aug; 11(4):723-33. PubMed ID: 7651736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.
    Will K; Warnecke G; Wiesmüller L; Deppert W
    Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13681-6. PubMed ID: 9811860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
    Thomas S; Reisman D
    Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro analysis of the dominant negative effect of p53 mutants.
    Chène P
    J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
    Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
    Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective binding of different p53 response elements by p53 containing complexes.
    Martinez JD; Craven MT; Pennington ME
    Oncogene; 1998 Jan; 16(4):453-8. PubMed ID: 9484834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
    Tarunina M; Jenkins JR
    Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro.
    Li H; Cao Y; Berndt MC; Funder JW; Liu JP
    Oncogene; 1999 Nov; 18(48):6785-94. PubMed ID: 10597287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.